RWM
ABBV icon

Revisor Wealth Management’s AbbVie ABBV Stock Holding History

Revisor Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$855K Buy
3,399
+25
+0.7% +$5.38K 0.21% 126
2026
Q1 		$733K Buy
3,374
+281
+9% +$62.3K 0.2% 125
2025
Q4 		$680K Sell
3,093
-288
-9% -$65.6K 0.18% 133
2025
Q3 		$778K Sell
3,381
-402
-11% -$81.9K 0.27% 83
2025
Q2 		$739K Sell
3,783
-126
-3% -$23.4K 0.27% 80
2025
Q1 		$819K Buy
3,909
+1,585
+68% +$308K 0.36% 56
2024
Q4 		$416K Sell
2,324
-1,797
-44% -$330K 0.38% 52
2024
Q3 		$814K Sell
4,121
-150
-4% -$28K 0.51% 38
2024
Q2 		$733K Sell
4,271
-2,758
-39% -$457K 0.51% 38
2024
Q1 		$1.18M Buy
7,029
+4,660
+197% +$803K 0.54% 38
2023
Q4 		$367K Sell
2,369
-1,102
-32% -$161K 0.42% 51
2023
Q3 		$517K Buy
3,471
+790
+29% +$116K 0.44% 48
2023
Q2 		$361K Sell
2,681
-56
-2% -$8.21K 0.32% 76
2023
Q1 		$436K Buy
+2,737
New +$418K 0.4% 62

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Revisor Wealth Management's ABBV Position: Q2 2026 in Review

Revisor Wealth Management increased its AbbVie (ABBV) stake by 0.74% in Q2 2026, buying an estimated $5.38K and bringing the position to 3,399 shares worth $855K. The position accounts for 0.21% of the portfolio, ranked #126.

Revisor Wealth Management first reported a position in ABBV in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.18M in Q1 2024. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Revisor Wealth Management held 3,399 shares of AbbVie worth $855K as of Q2 2026.
  • Revisor Wealth Management bought 25 AbbVie shares in Q2 2026, an estimated $5.38K.
  • AbbVie made up 0.21% of Revisor Wealth Management's portfolio in Q2 2026, its #126 holding.
  • Revisor Wealth Management first reported a position in AbbVie in Q1 2023 and has held it in 14 quarters since.
  • Revisor Wealth Management's AbbVie position peaked at $1.18M in Q1 2024.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Revisor Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.